BioVersys

BioVersys is a clinical stage biopharmaceutical company focused on the research and development of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation.

BioVersys' goal is to switch-off antibiotic resistances were they are first occurring and therefore expanding the lifetime of existing FDA-licensed antibiotics.

BioVersys was founded in 2008 by Marc Gitzinger. The company is headquartered in Basel, Basel-Town, Switzerland.

 

BioVersys' award-winning TRIC technology can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields.

 

BioVersys' lead candidate, BV100, is being developed for lung and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB). BioVersys' pipeline also includes BV200; BV300; and BVL-GSK098.

 

BioVersys' most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase II-ready), and tuberculosis (BVL-GSK098, Phase II-ready) in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille.

 

BioVersys is backed by AMR Action Fund, CARB-X, IMI2-JU/European Union, goetzpartners securities Limited, Mirabaud Securities Limited, and others. The company extented its Series C round to CHF 32.6M on Jan 05, 2023. This brings BioVersys' total funding to $99.6M to date.

 

 

  • Year founded: 2008
  • Funding Info: $99.6M over 6 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Basel
  • State: Basel-Town
  • Country: Switzerland
Related businesses